Related Experiment Video
Updated: Jun 24, 2026
07:50
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Orphan targets for reperfusion injury.
Javier Inserte1, José A Barrabés, Víctor Hernando
1Laboratorio de Cardiología Experimental, Servicio de Cardiología, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
Cardiovascular Research
|April 9, 2009
Summary
Preventing reperfusion injury, a major cause of heart attack damage, shows promise. New clinical trials suggest strategies targeting cell death mechanisms can reduce heart muscle damage, paving the way for new drug development.
Area of Science:
- Cardiology
- Cellular Biology
- Pharmacology
Background:
- Transient ischemia leads to cardiomyocyte death during reperfusion, primarily via contraction band necrosis.
- Mechanisms involve calcium handling alterations and consequences like hypercontracture and mitochondrial permeability transition pore (mPTP) opening.
Purpose of the Study:
- To review pharmacological targets for preventing lethal reperfusion injury.
- To discuss the clinical translation challenges and recent successes in targeting reperfusion injury.
Main Methods:
- Review of experimental studies on pharmacological interventions targeting reperfusion injury mechanisms.
- Analysis of recent proof-of-concept clinical trials for post-conditioning and mPTP inhibition.
Main Results:
- Pharmacological targets (e.g., Na+/H+-exchanger, mPTP) show promise in reducing infarct size in experimental models.
- Recent clinical trials demonstrate the feasibility of strategies like post-conditioning and mPTP inhibition in patients.
Conclusions:
- Clinical translation of reperfusion injury therapies has been limited by a lack of human-testable drugs.
- Emerging clinical evidence supports strategies targeting reperfusion injury, encouraging further drug development against validated targets.
